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Background. The optimum diagnostic test method for Clostridioides difficile infection (CDI) remains controversial due to var-
iation in accuracy in identifying true CDI. This post hoc analysis examined the impact of CDI diagnostic testing methodology on 
efficacy outcomes in phase 3 MODIFY I/II trials.
Methods. In MODIFY I/II (NCT01241552/NCT01513239), participants received bezlotoxumab (10 mg/kg) or placebo during 
anti-CDI treatment for primary/recurrent CDI (rCDI). Using MODIFY I/II pooled data, initial clinical cure (ICC) and rCDI were 
assessed in participants diagnosed at baseline using direct detection methods (enzyme immunoassay [EIA]/cell cytotoxicity assay 
[CCA]) or indirect methods to determine toxin-producing ability (toxin gene polymerase chain reaction [tgPCR]/toxigenic culture).
Results. Of 1554 participants who received bezlotoxumab or placebo in MODIFY I/II, 781 (50.3%) and 773 (49.7%) were diag-
nosed by tgPCR/toxigenic culture and toxin EIA/CCA, respectively. Participants diagnosed by toxin EIA/CCA were more likely to 
be inpatients, older, and have severe CDI. In bezlotoxumab recipients, ICC rates were slightly higher in the toxin EIA/CCA subgroup 
(81.7%) vs tgPCR/toxigenic culture (78.4%). Bezlotoxumab significantly reduced the rCDI rate vs placebo in both subgroups; how-
ever, the magnitude of reduction was substantially larger in participants diagnosed by toxin EIA/CCA (relative difference, –46.6%) 
vs tgPCR/toxigenic culture (–29.1%). In bezlotoxumab recipients, the rCDI rate was lower in the toxin EIA/CCA subgroup (17.6%) 
vs tgPCR/toxigenic culture (23.6%; absolute difference, –6.0%; 95% confidence interval, –12.4 to 0.3; relative difference, –25.4%).
Conclusions. Diagnostic tests that detect fecal C. difficile toxins are of fundamental importance to accurately diagnosing CDI, 
including in clinical trial design, ensuring that therapeutic efficacy is not underestimated.
Keywords. diagnosis; diarrhea; toxin; treatment outcome.
Clostridioides difficile is a Gram-positive, spore-forming an-
aerobe that resides naturally in the large intestine of up to 15% 
of the adult population [1]. Disruption of the normal intestinal 
microbiota, most commonly due to treatment with broad-spec-
trum antibiotics, can lead to the overgrowth of C. difficile [2, 3]. 
The subsequent production of C. difficile toxin A and B causes 
colonic inflammation, resulting in mild to severe diarrhea and 
abdominal pain and more serious manifestations, including ful-
minant colitis, severe leukocytosis, and death [3, 4].
There has been a marked increase in the incidence and se-
verity of C.  difficile infection (CDI) in recent years [5–7]. 
Although antibiotic treatment for primary CDI is often suc-
cessful, it has been reported that ~25% of individuals experi-
ence recurrent CDI after completing initial antibiotic therapy 
[8, 9]. After the first recurrent episode, individuals have a 38%–
45% probability of a second recurrence, with increasing risk 
with further recurrences [10, 11].
Bezlotoxumab (MK-6072), a fully human monoclonal anti-
body that binds to C.  difficile toxin B, is indicated to prevent 
recurrence of CDI (rCDI) in at-risk adults receiving antibac-
terial drug treatment for primary or recurrent CDI [12]. In the 
MODIFY I/II phase 3 trials, a single infusion of bezlotoxumab 
administered with or without actoxumab (a monoclonal anti-
body against C. difficile toxin A) resulted in a significantly lower 
rCDI rate over 12 weeks compared with placebo [13].
The study design of the MODIFY trials, including the defini-
tion of CDI and diagnostic methods used, was based on the 2010 
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Epidemiology of America (IDSA/SHEA) CDI guidelines [14]. 
Due to the absence of an optimal CDI diagnostic test at the 
time, these guidelines included several test methods in their re-
commendations. Stool culture followed by the identification of 
a toxigenic isolate (known as toxigenic culture) and cell cyto-
toxicity assay (CCA) testing were considered the gold standard; 
however, these methods were deemed impractical for routine 
diagnosis due to a long turnaround time [14]. Enzyme immu-
noassay (EIA) was considered to be most important clinically, 
but was limited by a lack of sensitivity [14]. Polymerase chain 
reaction (PCR) testing was described as a rapid, sensitive, and 
specific method, but more evidence was required to evaluate its 
utilization in routine diagnostic testing [14]. Consequently, a 
range of test methods was permitted for use by the local labora-
tories to diagnose CDI in participants enrolled in MODIFY I/II.
Since the 2010 IDSA/SHEA CDI guidelines were published, 
further research has clearly shown that the presence of toxigenic 
C. difficile alone (ie, toxin-negative) is not always indicative of 
clinical disease. Indeed, 4%–29% of hospitalized individuals are 
asymptomatic carriers of toxigenic C. difficile [1]. Furthermore, 
multiple studies have correlated the presence of C.  difficile 
toxins with clinical outcome, showing that individuals who 
have C. difficile toxin present in their stool (ie, toxin-positive) 
experience higher rCDI and mortality rates compared with in-
dividuals who have toxigenic C. difficile bacteria, but no toxin, 
in their stool (ie, toxin-negative) [15, 16]. These findings sug-
gest that toxigenic PCR and culture methods, which detect 
C. difficile bacteria regardless of toxin production, may not re-
flect true CDI.
Previous research has suggested that PCR-diagnosed individ-
uals may be less likely to respond to CDI treatment compared 
with those diagnosed using a direct toxin-based test [17–19]. As 
both direct and indirect test methods were used to diagnose CDI 
in MODIFY I/II, it is possible that the dilution of treatment-
responsive participants with non-treatment-responsive “false 
CDI” participants may have led to the underestimation of the 
therapeutic efficacy of bezlotoxumab. This post hoc analysis 
examined this hypothesis, with the aim to determine if the 
CDI diagnostic testing methodology used in MODIFY I/II 
had an impact on efficacy outcomes in participants receiving 
bezlotoxumab or placebo.
METHODS
Study Design
MODIFY I/II (NCT01241552/NCT01513239) were random-
ized, double-blind, placebo-controlled, multicenter, phase 3 
trials conducted between November 1, 2011, and May 22, 
2015, at 322 sites in 30 countries. Full trial details have previ-
ously been published [13]. Briefly, adults receiving a 10–14-
day regimen of antibacterial drug treatment (metronidazole, 
vancomycin, or fidaxomicin) for primary CDI or rCDI were 
randomized to receive a single infusion of bezlotoxumab 
(10 mg/kg of body weight) or actoxumab (10 mg/kg; MODIFY I  
only) or bezlotoxumab plus actoxumab (10  mg/kg each) or 
placebo (0.9% saline). CDI was defined as ≥3 unformed bowel 
movements (types 5 to 7 on the Bristol Stool Scale [20] in 
24 hours), with a positive stool test for toxigenic C. difficile.
In this post hoc analysis of pooled data from MODIFY I/II 
trials (including only participants who received bezlotoxumab 
or placebo), a number of end points were investigated through 
12 weeks in 2 subgroups: participants diagnosed at baseline via 
an indirect method (toxin gene PCR [tgPCR]/toxigenic cul-
ture) and participants diagnosed at baseline via a direct toxin 
detection method (toxin EIA/CCA). Different populations 
were included in the diagnostic subgroups; the toxin EIA/CCA 
subgroup only included toxin-positive participants, whereas 
the tgPCR/toxigenic culture subgroup likely included both 
toxin-positive and toxin-negative participants. All permitted 
commercial test kits had a labeled specificity of ≥94% with the 
capacity to detect the presence of C. difficile toxin B (toxin EIA 
kits) or its cognate tcdB gene (PCR kits).
End Points
The main efficacy end points included initial clinical cure (ICC) 
and rCDI. ICC was defined as no diarrhea during the 2 consec-
utive days after completion of ≤16 calendar days of anti-CDI 
treatment. rCDI was defined as a new episode of diarrhea asso-
ciated with a positive stool test for toxigenic C. difficile in parti-
cipants who had achieved the ICC of the baseline CDI episode; 
the diagnostic methods used for testing the stool of recurrent 
diarrhea episodes were preferably the same as those used for 
trial eligibility.
Other efficacy end points included sustained cure (de-
fined as clinical cure of the initial CDI episode and no rCDI 
through 12-week follow-up), diarrhea recurrence (a new epi-
sode of diarrhea in participants who had achieved ICC of the 
baseline CDI episode, regardless of whether a stool test for 
toxigenic C. difficile was positive, negative, or not performed), 
rehospitalization (the occurrence of 30-day all-cause and CDI-
associated hospital readmissions), fecal microbiota transplant 
(FMT; the receipt of an FMT at any time during the study), 
and all-cause mortality (the occurrence of death within 30 and 
90 days after randomization).
Statistical Analyses
The modified intent-to-treat (mITT) population was used for 
ICC estimations and included all randomized participants in 
the overall population of the MODIFY I/II trials who received 
the study infusion, had a positive baseline stool test for toxigenic 
C. difficile, and received anti-CDI treatment within 1 day of the 
study infusion. mITT participants who achieved ICC of the 
baseline CDI episode were included in rCDI and diarrhea recur-
rence estimations (clinical cure population). Rehospitalization 
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was estimated in mITT participants who were hospitalized at 
the time of randomization. Mortality was estimated using the 
“all patients as treated” population, which included all random-
ized participants who received the study infusion.
Initial and sustained cure rates, as well as observed rCDI 
and diarrhea recurrence rates, are presented, along with rate 
differences between the bezlotoxumab and placebo groups 
and their 95% confidence intervals (CIs). The 95% CIs are 
based on the Miettinen and Nurminen method [21]. Other 
outcomes, including rehospitalization, FMT, and mortality 
during the 12-week follow-up period, are summarized de-
scriptively using the frequency and percentage for each treat-
ment group.
Assay Interference Experiment
An assay interference experiment was performed to deter-
mine if the reduced rate of rCDI observed in bezlotoxumab-
treated participants diagnosed via toxin EIA/CCA compared 
with those diagnosed via tgPCR/toxigenic culture was a true 
result, rather than bezlotoxumab rendering diagnostic toxin 
EIA or CCA results falsely negative because of binding to free 
toxins present in fecal samples. Further detail is available in the 
Supplementary Data.
RESULTS
Participants
The integrated mITT population from MODIFY I/II consisted 
of 1554 participants, of whom 781 received bezlotoxumab 
and 773 received placebo. Baseline demographic and clin-
ical characteristics were generally similar between treatment 
groups [13]. In total, 781 (50.3%) participants were diag-
nosed by tgPCR/toxigenic culture: 399 (out of 781, 51.1%) 
participants in the bezlotoxumab group and 382 (out of 
773, 49.4%) participants in the placebo group. Overall, 773 
(49.7%) participants were diagnosed by toxin EIA/CCA: 382 
(out of 781, 48.9%) participants in the bezlotoxumab group 
and 391 (out of 773, 50.6%) participants in the placebo group 
(Table 1).
A toxin EIA kit was the most commonly used diagnostic test 
at baseline (48.7% of participants), followed by tgPCR (44.7%), 
toxigenic culture (5.6%), and CCA (1.1%) (Supplementary 
Table 1). Direct toxin detection methods (toxin EIA/CCA) 
were more common in Europe, whereas indirect toxin detec-
tion methods (tgPCR/toxigenic culture) were more common 
in North America (Table 1). Overall, the use of different test 
methods was balanced across treatment groups (Table 1).
In both treatment groups, a higher proportion of participants 
diagnosed via toxin EIA/CCA prematurely discontinued from 
the study (bezlotoxumab, 17.0%; placebo, 18.7%) vs tgPCR/tox-
igenic culture (bezlotoxumab, 11.5%; placebo, 13.9%). The most 
frequent reasons for discontinuation were death and participant 
withdrawal (Supplementary Table 2).
Compared with participants diagnosed via tgPCR/toxigenic 
culture, a higher proportion of participants diagnosed via toxin 
EIA/CCA were inpatients at the time of randomization, were 
older, and had severe CDI (Zar score ≥ 2) or ≥1 of 5 prespecified 
risk factors for rCDI (Table 1).
Initial Clinical Cure
ICC rates were slightly lower in participants diagnosed via 
tgPCR/toxigenic culture (bezlotoxumab, 78.4%; placebo, 77.7%) 
vs toxin EIA/CCA (bezlotoxumab, 81.7%; placebo, 82.9%), with 
a similar rate between treatment groups (Figure 1).
CDI Recurrence
Compared with placebo, bezlotoxumab significantly reduced 
the rCDI rate regardless of diagnostic method, with an abso-
lute difference of –15.4% (95% CI, –22.0% to –8.7%) and –9.7% 
(95% CI, –16.8% to –2.5%) in the toxin EIA/CCA and tgPCR/
toxigenic culture subgroups, respectively (Figure 2). Among 
bezlotoxumab-treated participants, the rCDI rate tended to be 
lower in participants diagnosed by toxin EIA/CCA (17.6%) vs 
tgPCR/toxigenic culture (23.6%; absolute difference, –6.0%; 
95% CI, –12.4% to 0.3%; relative difference –25.4%). In con-
trast, rCDI was ~33% in the placebo group regardless of diag-
nostic method (Figure 2). The relative reduction in rCDI rate 
for bezlotoxumab- vs placebo-treated participants was higher 
at 46.6% for toxin EIA/CCA vs 29.1% for tgPCR/toxigenic cul-
ture (Figure 3).
CDI Recurrence Stratified by Baseline Demographic and Clinical 
Characteristic Subgroups
Across the majority of baseline demographic and clinical char-
acteristic subgroups in the treatment and placebo arms, rCDI 
rates were lower in participants diagnosed with toxin EIA/CCA 
(Figure 3A) vs tgPCR/toxigenic culture (Figure 3B). Absolute 
differences in rCDI between the bezlotoxumab and placebo 
groups were also larger in participants diagnosed by toxin EIA/
CCA in these subgroups; however, the 95% CIs of the difference 
included 0 in some subgroups (Figure 3). In participants with 
primary CDI (ie, no CDI in the past 6 months), the absolute 
reduction in rCDI rate was greater in those diagnosed by toxin 
EIA/CCA (13.5%) compared with tgPCR/toxigenic culture 
(5.3%; 95% CIs included 0). A similar trend was observed for 
inpatients, metronidazole-treated participants, and European 
participants (Figure 3).
A sensitivity analysis was also conducted that investigated 
the proportion of participants who experienced diarrhea re-
currence irrespective of an association with C. difficile. Here, 
a similar trend was observed, with lower diarrhea recurrence 
rates in the toxin EIA/CCA subgroup vs the tgPCR/toxigenic 
culture subgroup (Supplementary Table 3). Additionally, a 
higher proportion of participants diagnosed via toxin EIA/
CCA achieved sustained cure vs tgPCR/toxigenic culture 
(Supplementary Table 4).
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Assay Interference Experiment
Compared with control samples incubated without bezlotoxumab, 
incubation of fecal samples with the median observed stool con-
centration of bezlotoxumab (528.0  ng/mL) (Supplementary 
Data) did not change diagnostic toxin EIA or CCA results 
(Supplementary Table 5). Compared with control samples, incu-
bation of samples with higher bezlotoxumab concentrations (10× 
median, 100× median) had no effect on diagnostic EIA results, 
but changed the diagnostic result from positive to negative in 
some samples tested by CCA (Supplementary Table 5).
Other Outcomes
In participants in both treatment groups who were inpatients 
at the time of randomization, the all-cause rehospitalization 
Table 1. Baseline Demographics and Clinical Characteristics in the mITT Population by Treatment Group and Diagnostic Method
Bezlotoxumab Placebo 
 EIA + CCA,No.a (%) PCR + Culture,No.a (%) EIA + CCA,No.a (%) PCR + Culture,No.a (%)
Participants in population 382 399 391 382 
 Inpatient 299 (78.3) 231 (57.9) 307 (78.5) 213 (55.8)
 Female 212 (55.5) 230 (57.6) 235 (60.1) 214 (56.0)
 Mean age (SD), y 65.7 (16.8) 58.2 (18.4) 65.4 (17.9) 61.5 (16.7) 
  Median 69 60 68 63
  Range 21–100 18–97 19–98 18–97 
 Age ≥65 y 226 (59.2) 164 (41.1) 230 (58.8) 175 (45.8)
 ≥1 CDI episodes in past 6 mo 93 (24.3) 123 (30.8) 114 (29.2) 105 (27.5)
 ≥2 previous CDI episodes ever 41 (10.9) 59 (15.0) 61 (15.8) 65 (17.6) 
 Severe CDI (Zar score ≥ 2)b 72 (18.8) 50 (12.5) 77 (19.7) 48 (12.6) 
 Immunocompromisedc 81 (21.2) 97 (24.3) 72 (18.4) 81 (21.2) 
 Antibiotic used during ADT 131 (34.3) 115 (28.8) 142 (36.3) 134 (35.1)
 Antibiotic used after ADT 131 (34.3) 115 (28.8) 110 (28.1) 114 (29.8)
 At least 1 of the 5 predefined risk factorse 304 (79.6) 288 (72.2) 313 (80.1) 270 (70.7)
 Charlson Comorbidity Index ≥3 170 (44.5) 149 (37.3) 157 (40.2) 146 (38.2)
 Albumin <2.5 g/dL 63 (16.5) 38 (9.5) 58 (14.8) 45 (11.8) 
 Renal impairmentf 68 (17.8) 55 (13.8) 53 (13.6) 57 (14.9) 
 Hepatic impairmentg 30 (7.9) 19 (4.8) 24 (6.1) 20 (5.2)
Antibiotic drug treatment for CDI     
 Metronidazole 191 (50.0) 188 (47.1) 193 (49.4) 181 (47.4)
 Vancomycin 176 (46.1) 196 (49.1) 187 (47.8) 186 (48.7)
 Fidaxomicin 15 (3.9) 15 (3.8) 11 (2.8) 15 (3.9)
PCR ribotypeh     
 Participants with a positive culture 237 253 250 236 
 027, 078, or 244 strain 58 (24.5) 44 (17.4) 71 (28.4) 44 (18.6) 
 027 strain 54 (22.8) 35 (13.8) 64 (25.6) 36 (15.3) 
Regioni     
 Africa 0 (0.0) 5 (1.3) 0 (0.0) 2 (0.5) 
 Asia-Pacific 57 (14.9) 22 (5.5) 53 (13.6) 24 (6.3)
 Europe 205 (53.7) 108 (27.1) 187 (47.8) 106 (27.7)
 Latin America 21 (5.5) 9 (2.3) 26 (6.6) 9 (2.4) 
 North America 99 (25.9) 255 (63.9) 125 (32.0) 241 (63.1)
Abbreviations: ADT, antibacterial drug treatment; ALT, alanine aminotransferase; CDI, Clostridioides difficile infection; CCA, cell cytotoxicity assay; EIA, enzyme immunoassay; mITT, modified 
intent-to-treat; PCR, polymerase chain reaction; ULN, upper limit of normal; WBC, white blood cell.
aNo. represents the number of participants in the subgroup analysis population meeting the criteria for the end point.
bBased on the following: (1) age >60 years (1 point), (2) body temperature >38.3°C (>100°F; 1 point), (3) albumin level <2.5 g/dL (1 point), (4) peripheral WBC count >15 000 cells/mm
3 within 
48 hours (1 point), (5) endoscopic evidence of pseudomembranous colitis (2 points), and (6) treatment in an intensive care unit (2 points).
cDefined on the basis of a subject’s medical history or use of immunosuppressive therapy.
dSystemic antibiotic other than ADT given to treat CDI.
ePredefined risk factors include CDI history in the past 6 months, severe CDI at baseline (per Zar score), age ≥65 years, having a hypervirulent strain (027, 078, or 244 ribotypes) at baseline, 
and immunocompromised.
fRenal impairment defined as serum creatinine ≥1.5 mg/dL.
gHepatic impairment defined by 2 or more of the following: (a) albumin ≤3.1 g/dL, (b) ALT ≥2× ULN, (c) total bilirubin ≥1.3× ULN, or (d) mild, moderate, or severe liver disease (as reported 
on the Charlson Comorbidity Index).
hDenominator is participants in the mITT population with a positive culture.
iAfrica includes South Africa. Asia-Pacific includes Australia, Japan, Korea, New Zealand, and Taiwan. Latin America includes Argentina, Brazil, Chile, Colombia, and Mexico. Europe includes 
Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Poland, Portugal, the Russian Federation, Spain, Sweden, Switzerland, Turkey, and the United Kingdom. 
North America includes Canada and the United States.
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rate was higher in those diagnosed with tgPCR/toxigenic cul-
ture vs toxin EIA/CCA (Table 2). In contrast, in both treat-
ment groups, there was a trend for higher CDI-associated 
rehospitalization rates in participants diagnosed with toxin 
EIA/CCA vs tgPCR/toxigenic culture (Table 2). Similarly, 
there was a trend for higher mortality in participants diag-
nosed with toxin EIA/CCA vs tgPCR/toxigenic culture in both 
treatment groups (Table 2). Compared with the bezlotoxumab 
group, a higher proportion of placebo-treated participants 
had an FMT procedure during the follow-up period, regard-
less of diagnostic method (Table 2).
DISCUSSION
CDI diagnosis is based on clinical presentation and laboratory 
testing, although the methodology for the latter remains con-
troversial. Increasing evidence supports the higher predictive 
value of toxin detection rather than the presence of a strain with 
the capacity to produce toxin (ie, toxigenic culture or toxin gene 
detection) [14, 23]. As several different test methods were used 
to diagnose CDI in MODIFY I/II, it was important to establish 
if this had an effect on the measured efficacy of bezlotoxumab.
In these 2 trials, almost equal proportions of participants 
in the bezlotoxumab and placebo groups were diagnosed via 
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tgPCR/toxigenic culture vs toxin EIA/CCA, which reflects the 
diagnostic variability at the time of trial design [14].
Our post hoc analysis demonstrates that bezlotoxumab was 
associated with clinically meaningful reductions in rCDI rates 
compared with placebo, regardless of the diagnostic method 
used; however, the magnitude of reduction of rCDI associated 
with bezlotoxumab was substantially higher among partici-
pants diagnosed by toxin EIA/CCA vs tgPCR/toxigenic culture. 
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Figure 3. The proportion of participants who experienced rCDI according to subgroup (clinical cure population; MODIFY I and II pooled data). A, Subgroup results for 
participants diagnosed by toxin EIA or CCA. B, Subgroup results for participants diagnosed by tgPCR or toxigenic culture. aNo. represents the number of participants in the 
subgroup analysis population meeting the criteria for the end point; n represents the number of participants within the subgroup. Abbreviations: CCA, cell cytotoxicity assay; 
CDI, Clostridioides difficile infection; EIA, enzyme immunoassay; rCDI, recurrent Clostridioides difficile infection; tgPCR, toxin gene polymerase chain reaction.
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Notably, a similar trend in rCDI reduction was also observed 
across subgroup and sensitivity analyses. Furthermore, results 
from the assay interference experiment suggest that the trend 
in rCDI reduction is a true result rather than an artefact present 
due to falsely negative toxin EIA/CCA results, as exposure of 
fecal samples to physiological levels of bezlotoxumab generally 
had no effect on the results derived by either diagnostic test. 
As the bezlotoxumab stock had to be diluted to meet the fecal 
concentrations required, the change in diagnostic CCA results 
from positive to negative observed in some samples may have 
been due to a dilution effect.
ICC rates also tended to be slightly higher in participants 
diagnosed with toxin EIA/CCA compared with tgPCR/toxi-
genic culture, which was evident in both the bezlotoxumab and 
placebo groups. This is plausibly because participants diagnosed 
via toxin EIA/CCA were more likely to have CDI-related diar-
rhea, and thus to have a better response to CDI treatment com-
pared with participants diagnosed by tgPCR/toxigenic culture 
(who may not have had true CDI) [16]. The larger reduction 
in rCDI could be partly explained by the difference in baseline 
characteristics, as there were more inpatients, older partici-
pants, and severe CDI cases in the toxin EIA/CCA subgroup vs 
the tgPCR/toxigenic culture subgroup at baseline; however, this 
is unlikely, as a lower reduction in rCDI in older participants 
with severe CDI would be expected.
In addition, a higher proportion of participants diagnosed via 
toxin EIA/CCA, vs tgPCR/toxigenic culture, prematurely discon-
tinued from the study. There was also a trend for higher mortality 
rates in participants diagnosed by toxin EIA/CCA compared 
with tgPCR/toxigenic culture. Similarly, this could be partly in-
fluenced by the difference in baseline participant characteristics.
Our findings are consistent with previous post hoc clinical 
trial analyses, which have also suggested that CDI treatment is 
less efficacious in PCR-diagnosed individuals compared with 
those diagnosed using a toxin-based test [17–19]. Furthermore, 
our findings are consistent with recent data suggesting a corre-
lation between the presence of fecal C. difficile toxins and true 
CDI. Planche and colleagues previously reported that mortality 
rates were significantly higher in individuals who were con-
firmed to be toxin-positive, compared with those who were 
toxin-negative, but had a positive toxigenic culture test result 
[15]. Similarly, in another study of hospitalized patients with 
suspected CDI, virtually all CDI-related complications and 
deaths occurred in toxin-positive individuals [16].
It has been speculated that exclusive reliance on diagnostic 
tests that only detect toxigenic C.  difficile strains may lead to 
over-reporting of CDI cases. Indeed, a number of studies have 
shown that performing tgPCR instead of toxin EIA or CCA 
to diagnose CDI can lead to increases of ~50% in CDI rates 
[24–26]. In another study, the use of tgPCR vs toxin EIA was 
associated with inadequacies in the performance tool used to 
assess institutional CDI rates. This was due to a failure in the 
risk-adjustment approach, designed to correct for the use of 
different diagnostic test methods between institutions, which 
could lead to false reporting of high CDI rates in some institu-
tions [27].
Notably, almost half of the participants enrolled in 
MODIFY I/II were not diagnosed using a toxin-based test; 
therefore, some of these participants may have had an alternate 
cause of diarrhea. This likely explains why bezlotoxumab was 
associated with a lower magnitude of reduction in rCDI rate in 
participants diagnosed by tgPCR/toxigenic culture.
Although recent treatment guidelines acknowledge the diag-
nostic concern regarding molecular tests that only detect the 
presence of C.  difficile toxin genes, the choice of tgPCR and 
toxin-based testing is still included in their recommendations 
Table 2. Proportion of Participants Who Experienced Rehospitalization, FMT, or Mortality (MODIFY I and II Pooled Data)
Bezlotoxumab Placebo
 Toxin EIA + CCA,a No./nb (%) tgPCR + Culture,a No./nb (%) Toxin EIA + CCA,a No./nb (%) tgPCR + Culture,a No./nb (%)
Rehospitalizationc     
 Any 63/299 (21.1) 60/231 (26.0) 80/307 (26.1) 60/213 (28.2)
 Associated with CDId 16/299 (5.4) 11/231 (4.8) 39/307 (12.7) 19/213 (8.9)
Received an FMTe 2/382 (0.5) 5/399 (1.3) 13/391 (3.3) 10/382 (2.6)
Mortalityf     
 30-d mortality 17/382 (4.5) 10/404 (2.5) 15/394 (3.8) 12/387 (3.1)
 90-d mortality 35/382 (9.2) 19/404 (4.7) 35/394 (8.9) 24/387 (6.2)
Abbreviations: CCA, cell cytotoxicity assay; CDI, Clostridioides difficile infection; EIA, enzyme immunoassay; FMT, fecal microbiota transplant; mITT, modified intent-to-treat; rCDI, recurrent 
Clostridioides difficile infection; tgPCR, toxin gene polymerase chain reaction.
aDiagnostic subgroups are based on the test method used to diagnose the baseline CDI episode.
bNo. represents the number of participants in the subgroup analysis population meeting the criteria for the end point; n represents the number of participants within the subgroup.
cmITT population who were inpatients at the time of randomization.
dCDI-associated rehospitalization was defined as a 30-day readmission based on ≥1 of the following: readmission that occurred within 5 days after onset of a new CDI episode, onset of a 
new CDI episode during readmission, or the inclusion of terms synonymous with CDI, rCDI, or pseudomembranous colitis in the discharge diagnosis, as recorded on the trial case report 
form [22].
emITT population.
fAll participants as treated population.
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[28, 29]. This study provides important, therapy-based data on 
the most appropriate method of diagnosing true CDI. The re-
sults presented here support the fundamental importance of 
fecal C.  difficile toxin detection in accurately determining if 
CDI is truly present and, therefore, identifying patients with 
treatment-responsive disease. This has multiple practical im-
plications, notably regarding optimal patient management and 
design of clinical trials for new therapies.
The results presented here also suggest that the efficacy of 
bezlotoxumab in preventing rCDI may be higher than first re-
ported. In the primary analysis of MODIFY I/II in the overall 
population, bezlotoxumab was associated with absolute rCDI 
rate reductions of 12.2% and 10.0% in the clinical cure and 
mITT populations, respectively, compared with placebo [13]. 
Here, we demonstrate that in the toxin EIA/CCA subgroup, 
bezlotoxumab was associated with an absolute reduction of 
15.4% compared with placebo. Furthermore, the efficacy of 
bezlotoxumab at preventing rCDI in high-risk subgroups could 
also have been previously under-reported. Indeed, a previous 
analysis of MODIFY I/II showed that, compared with placebo, 
bezlotoxumab was associated with an absolute reduction of 
15.9% in participants with ≥1 risk factor for CDI [30]. Here, 
we demonstrate that in participants with ≥1 risk factor who 
were diagnosed by toxin EIA/CCA, bezlotoxumab was asso-
ciated with an absolute reduction of 18.5% compared with 
placebo. These results provide additional evidence to suggest 
that individuals with ≥1 risk factor for rCDI may benefit from 
bezlotoxumab, adding further clarification on which individ-
uals may be suitable for bezlotoxumab treatment.
Study limitations include the fact that this was a post hoc anal-
ysis; the study was not designed to evaluate the impact of diag-
nostic method on the measured efficacy of bezlotoxumab. As 
such, the results can only be interpreted as trends rather than 
conclusive. In addition, multiple factors may have contributed to 
the observed difference in efficacy between diagnostic subgroups. 
Toxin-based testing was not performed in participants diagnosed 
via tgPCR/toxigenic culture; therefore, it is unknown if these 
participants had C. difficile toxins present in their stool. As rCDI 
episodes were confirmed using either direct C. difficile toxin de-
tection methods (EIA/CCA) or indirect methods to determine 
toxin-producing ability (tgPCR/toxigenic culture), it is possible 
that some participants did not have true rCDI and thus had an 
alternative cause of diarrhea recurrence. In conclusion, the choice 
of diagnostic test is fundamentally important in making an ac-
curate diagnosis of CDI, as demonstrated here in clinical trial 
design, to ensure that therapeutic efficacy is not underestimated.
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